נגישות
menu      
חיפוש מתקדם
תחביר
חפש...
הספר "אוצר וולקני"
אודות
תנאי שימוש
ניהול
קהילה:
אסיף מאגר המחקר החקלאי
פותח על ידי קלירמאש פתרונות בע"מ -
Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: Effect of halofuginone
Year:
1996
Authors :
פינס, מרק
;
.
קנופוב, ויקטור
;
.
Volume :
106
Co-Authors:
Levi-Schaffer, F., Department of Pharmacology, Hebrew University of Jerusalem, Jerusalem, Israel
Nagler, A., Dept. of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel
Slavin, S., Dept. of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel
Knopov, V., Institute of Animal Science, Agricultural Research Organization, Volcani Center, Bet Dagan, Israel
Pines, M., Institute of Animal Science, Agricultural Research Organization, Volcani Center, Bet Dagan, Israel, Institute of Animal Science, Volcani Center, ARO, Bet Dagan 50250, Israel
Facilitators :
From page:
84
To page:
88
(
Total pages:
5
)
Abstract:
The effect of halofuginone, a plant alkaloid known to inhibit collagen type I synthesis, on skin collagen content and skin morphology was evaluated in two in vivo models of scleroderma: the murine chronic graft-versus-host disease (cGvHD) and the tight skin mouse. Skin collagen was assessed by hydroxyproline levels in skin biopsies and by immunohistochemistry using anti-collagen type I antibodies. Daily intraperitoneal injections of halofuginone (1 μg/mouse) for 52 d starting 3 d before spleen cell transplantation, abrogated the increase in skin collagen and prevented the thickening of the dermis and the loss of the subdermal fat, all of which are characteristic of the cGvHD mice. Halofuginone had a minimal effect on collagen content of the control mice. The halofuginone-dependent decrease in skin collagen content was concentration-dependent and was not accompanied by changes in body weight in either the cGvHD or the control mice. Injections of halofuginone (1 μg/mouse) for 45 d caused a decrease in the collagen content and dermis width in tight skin mice, but did not affect the dermis width of control mice. Collagen content determination from skin biopsies confirmed the immunohistochemical results in the same mice. The low concentration of halofuginone needed to prevent collagen deposition in fibrotic skin without affecting body weight suggests that halofuginone may serve as a novel and promising anti-fibrotic therapy.
Note:
Related Files :
animal experiment
animal model
Animals
animal tissue
Fibrosis
graft versus host reaction
mice
עוד תגיות
תוכן קשור
More details
DOI :
Article number:
Affiliations:
Database:
סקופוס
Publication Type:
מאמר
;
.
Language:
אנגלית
Editors' remarks:
ID:
32244
Last updated date:
02/03/2022 17:27
Creation date:
17/04/2018 01:08
Scientific Publication
Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: Effect of halofuginone
106
Levi-Schaffer, F., Department of Pharmacology, Hebrew University of Jerusalem, Jerusalem, Israel
Nagler, A., Dept. of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel
Slavin, S., Dept. of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel
Knopov, V., Institute of Animal Science, Agricultural Research Organization, Volcani Center, Bet Dagan, Israel
Pines, M., Institute of Animal Science, Agricultural Research Organization, Volcani Center, Bet Dagan, Israel, Institute of Animal Science, Volcani Center, ARO, Bet Dagan 50250, Israel
Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: Effect of halofuginone
The effect of halofuginone, a plant alkaloid known to inhibit collagen type I synthesis, on skin collagen content and skin morphology was evaluated in two in vivo models of scleroderma: the murine chronic graft-versus-host disease (cGvHD) and the tight skin mouse. Skin collagen was assessed by hydroxyproline levels in skin biopsies and by immunohistochemistry using anti-collagen type I antibodies. Daily intraperitoneal injections of halofuginone (1 μg/mouse) for 52 d starting 3 d before spleen cell transplantation, abrogated the increase in skin collagen and prevented the thickening of the dermis and the loss of the subdermal fat, all of which are characteristic of the cGvHD mice. Halofuginone had a minimal effect on collagen content of the control mice. The halofuginone-dependent decrease in skin collagen content was concentration-dependent and was not accompanied by changes in body weight in either the cGvHD or the control mice. Injections of halofuginone (1 μg/mouse) for 45 d caused a decrease in the collagen content and dermis width in tight skin mice, but did not affect the dermis width of control mice. Collagen content determination from skin biopsies confirmed the immunohistochemical results in the same mice. The low concentration of halofuginone needed to prevent collagen deposition in fibrotic skin without affecting body weight suggests that halofuginone may serve as a novel and promising anti-fibrotic therapy.
Scientific Publication
You may also be interested in